Methyl 1-oxo-1,2,3,4-tetrahydroisoquinoline-7-carboxylate, 98%, 1g

2-(2,3-Dihydro-1H-inden-5-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane, 95.0%, 5g

2-(thiophen-2-yl)-2,3,4,5-tetrahydro-1H-1,5-benzodiazepine, 95.0%, 2g

5-Acetyl-2-methylpyridine, 97.0%, 1g

(3-Bromo-5-(trifluoromethyl)pyridin-2-yl)methanol, 95.0%, 250mg

(2r)-2-Hydroxypropanimidamide hydrochloride, 98%, 1g

Methyl 2-ethynylisonicotinate, 95.0%, 1g

5-Methylsalicylic acid, min. 98%, for synthesis, 1 g, glass packaging

(2E)-1-(4-bromophenyl)-3-(2,3,4-trimethoxyphenyl)prop-2-en-1-one, 95.0%, 10g

Ethyl 3-Bromoindole-2-carboxylate>95.0%(GC)5g

(R)-1-(3,5-Dichlorophenyl)ethanamine hydrochloride, 95.0%, 250mg

5'-Chloro-2'-fluoroacetophene, 98.0%, 10g

Sodium 2-(2-aminophenyl)-2-oxoacetate, 95.0%, 250mg